Antibody responses to SARS-CoV-2 in patients with COVID-19

QX Long, BZ Liu, HJ Deng, GC Wu, K Deng, YK Chen… - Nature medicine, 2020 - nature.com
We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within
19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G …

[HTML][HTML] Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

QX Long, XJ Tang, QL Shi, Q Li, HJ Deng, J Yuan… - Nature medicine, 2020 - nature.com
The clinical features and immune responses of asymptomatic individuals infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been well described. …

Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

K Wang, QX Long, HJ Deng, J Hu… - Clinical Infectious …, 2021 - academic.oup.com
Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed
vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics …

A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019

X Cai, J Chen, J li Hu, Q Long, H Deng… - The Journal of …, 2020 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus,
causes severe pneumonia and has spread throughout the globe rapidly. The …

D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity

J Hu, CL He, QZ Gao, GJ Zhang, XX Cao, QX Long… - BioRxiv, 2020 - biorxiv.org
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The spike (S) protein that mediates SARS-CoV-2 entry into host …

Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

Q Long, H Deng, J Chen, J Hu, B Liu, P Liao, Y Lin… - MedRxiv, 2020 - medrxiv.org
Background We aim to investigate the profile of acute antibody response in COVID-19 patients,
and provide proposals for the usage of antibody test in clinical practice. Methods A multi-…

[HTML][HTML] The clinical and immunological features of pediatric COVID-19 patients in China

J Chen, ZZ Zhang, YK Chen, QX Long, WG Tian… - Genes & diseases, 2020 - Elsevier
In December 2019, the corona virus disease 2019 (COVID-19) caused by novel coronavirus
(SARS-CoV-2) emerged in Wuhan, China and rapidly spread worldwide. Few information …

[HTML][HTML] Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx

…, ZZ Zhang, XF Cai, Y Hu, WL Zhang, QX Long… - Journal of …, 2021 - Elsevier
Background & Aims Current antiviral therapies help keep HBV under control, but they are
not curative, as they are unable to eliminate the intracellular viral replication intermediate …

APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients

H Zhang, L Shao, Z Lin, QX Long, H Yuan… - … and Targeted Therapy, 2022 - nature.com
Apolipoprotein E (APOE) plays a pivotal role in lipid including cholesterol metabolism. The
APOE ε4 (APOE4) allele is a major genetic risk factor for Alzheimer’s and cardiovascular …

[PDF][PDF] SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation …

…, XF Cai, H Tang, Y Hu, WL Zhang, X Liu, QX Long… - …, 2018 - Wiley Online Library
Hepatitis B virus (HBV) infection remains a major health problem worldwide. Maintenance
of the covalently closed circular DNA (cccDNA), which serves as a template for HBV RNA …